Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Shares of Sage Therapeutics (SAGE) were up 8.6% ahead of the opening bell on Monday, trading at $51.50. The Cambridge, Mass. company unveiled encouraging top-line results from part A of its phase 2 study of SAGE-217 for the treatment of major depressive disorder. "Understanding the caveats associated with open-label data, we are highly encouraged by the strong signal we achieved in this study, which met our internal criteria for achieving a positive signal and thus supported our plan to proceed to the double-blind, placebo-controlled part of the Phase 2 trial," said Sage CEO Jeff Jonas in a statement.

Meanwhile, Immunomedics (IMMU) shares rose 8% to $5.65 after finishing Friday's trading session at $5.23, up 21.6%. The Morris Plains, N.J. company on Friday announced a global licensing agreement with Seattle Genetics (SGEN) for sacituzumab govitecan, Immunomedics' solid tumor therapy candidate.

Other biotech stock movers on Monday morning include molecular diagnostic company Myriad Genetics (MYGN) , whose shares were up 6.2%, to $16.98.

More from Stocks

Our Columnists Talk General Electric

Our Columnists Talk General Electric

Dow Falls Sharply as Apple's Slump Offsets Gains in General Electric

Dow Falls Sharply as Apple's Slump Offsets Gains in General Electric

Video: When Analyzing General Electric, Take Stock of Your Cost Basis

Video: When Analyzing General Electric, Take Stock of Your Cost Basis

Cigarette Stocks Have Been Smoked This Week -- Here's a Top Trade

Cigarette Stocks Have Been Smoked This Week -- Here's a Top Trade

What Do Trade Wars Mean for High Yield Bond Investors?

What Do Trade Wars Mean for High Yield Bond Investors?